Zhou J, et al. - Whether subcutaneous immunotherapy (SCIT) confers long-term efficacy as well as safety as a treatment choice for cases with atopic dermatitis (AD) sensitized to house-dust mite (HDM), was investigated by performing a retrospective study of 378 patients with HDM-sensitized AD. SCIT plus pharmacotherapy was given to 164 patients for 3 years (SCIT group) and only pharmacotherapy was administered to the other 214 patients (non-SCIT group). Experts examined participants via scoring atopic dermatitis and pruritus visual analog scale scores, laboratory test findings, and adverse effects. They found that in cases with moderate-to-severe AD with HDM sensitization, a significant reduction in the severity as well as pruritus of this disease condition can be conferred by 3 years of SCIT. HDM SCIT can also be beneficial for cases that are multisensitized. Long-term impacts, such as prophylaxis of neoallergen sensitization as well as inhibition of the allergy march, can be achieved.